The Latest Breaking News from Novo Nordisk

Eli Lilly and Novo Nordisk fell Wednesday after Roche released positive early-stage trial data on its oral weight-loss drug.

Novo had last year applied to Dutch authorities for a coverage of the drug under its insurance

Novo Nordisk stock popped Friday after a study showed its diabetes and weight-loss drug could lower the risk of developing dementia.

Small pharmacies find difficulty in prescribing the drug due to Big Pharma restrictions on the industry. ‌

Arm stock and Nvidia chipmaker Taiwan Semiconductor are among the best global stocks to buy and watch on the stock market today.

With strong first-quarter results and promising growth in its diabetes and obesity treatments, all eyes are on Novo Nordisk’s (NVO) to see if the pharmaceutical giant can maintain its momentum. Will the upcoming second-quarter earnings report reflect its market potential? Learn more to find out….

As nearly $1 billion of venture capital dollars have been injected into weight-loss startups since 2023, companies are making unproven claims to attract customers. It’s a new twist on a story as old as the diet industry.

Shares in Novo Nordisk were down 1.1% after the study

Patients lost more significantly more weight on Eli Lilly's Mounjaro than Novo Nordisk's Ozempic, according to a new study.

Patients taking Eli Lilly's new drug Mounjaro achieved significantly greater weight loss than those on Novo Nordisk's Ozempic, a head-to-head study published Monday showed.

Southern Copper and gold stock Agnico eagle surged above early buy points on hopeful signs for U.S. and China policy.